サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1787194

多重がん早期発見の世界市場

Multi Cancer Early Detection

出版日
ページ情報
英文 214 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
多重がん早期発見の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 214 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の多重がん早期発見の市場規模は2030年までに26億米ドルに達する

世界の多重がん早期発見の市場規模は、2024年に11億米ドルと推定され、分析期間2024～2030年にCAGR15.6%で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである遺伝子パネル＆LDTは、CAGR13.8％を記録し、分析期間終了までに14億米ドルに達すると予測されます。リキッドバイオプシーセグメントの成長率は、分析期間でCAGR18.2%と推定されます。

米国市場は2億9,600万米ドルと推定、中国はCAGR20.4％で成長すると予測

米国の多重がん早期発見市場は、2024年に2億9,600万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億5,680万米ドルの市場規模に達すると予測され、分析期間2024～2030年のCAGRは20.4%です。その他の注目すべき地域市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.7%と13.9%と予測されています。欧州では、ドイツがCAGR約12.4%で成長すると予測されています。

世界の多重がん早期発見市場- 主要動向と促進要因のまとめ

多重がん早期発見はどのようにがん診断学を再編成しているのか？

がん診断に革命をもたらす画期的な技術である多重がん早期発見（MCED）の登場により、がん発見の状況は激変しつつあります。乳がんのマンモグラムや大腸がんの大腸内視鏡検査など、一部の悪性腫瘍のみを対象とする従来のがん検診とは異なり、MCED検査では、先進的なゲノム、エピゲノム、プロテオミクスバイオマーカーを活用し、1回の検査で複数のがん種を同時に検出します。これは、血液サンプル中の循環腫瘍DNA（ctDNA）、RNAシグネチャー、その他の分子変化を分析するリキッドバイオプシーによって達成されます。がんは依然として世界の死亡原因のトップであるため、早期発見は生存率を向上させる上で極めて重要です。世界保健機関（WHO）によると、がん関連死のかなりの割合を後期診断が占めており、早期、非侵襲的、包括的なスクリーニング・ソリューションの緊急の必要性が浮き彫りになっています。人工知能（AI）と機械学習（ML）アルゴリズムがバイオマーカー同定を強化することで、MCED検査は現在、これまで以上に正確で、拡張性があり、利用しやすくなっています。いくつかのバイオテクノロジー企業や研究機関は、大規模な臨床試験を通じてこれらの検査を検証する上で大きな進歩を遂げ、症状が現れる前からがんを特定できる可能性を実証しています。末期がん診断の負担を軽減し、患者の転帰を改善することが期待されることから、医療界、投資家、規制当局のいずれにおいても、かつてない興奮が巻き起こっています。

MCEDの進歩において、リキッドバイオプシーとAIはどのような役割を果たすのか？

MCED技術の中核には、リキッドバイオプシーと人工知能の統合があります。この2つの革新的技術は、多重がんスクリーニングの精度と効率を大幅に向上させました。従来の組織生検は効果的ではありますが、侵襲的で費用がかかり、特定のがん種に限定されることが多いです。対照的に、液体生検は低侵襲で、血流中の腫瘍由来の遺伝子断片を同定することにより、広範ながんを検出することができます。この技術は、進行するまで診断されないことが多い膵臓、卵巣、食道の悪性腫瘍など、スクリーニングが困難ながんの発見に特に有益です。AIによるパターン認識は、遺伝子、プロテオミクス、代謝マーカーの膨大なデータセットを迅速に分析し、良性シグナルと悪性シグナルを区別することで、MCEDの力をさらに増幅させます。何百万もの患者サンプルで訓練されたAIモデルは、診断精度を高め、偽陽性・偽陰性を最小限に抑え、検出されたがんの発生組織を予測することさえできます。MCEDにおけるAIの採用拡大により、アルゴリズムが新たながんサブタイプを認識し、新たな分子発見に適応するように進化する継続的学習も可能になりました。特に、GRAIL、Guardant Health、Exact Sciencesなどの企業は、AIを活用したリキッドバイオプシー検査の商品化に率先して取り組んでおり、その有効性を裏付ける広範な臨床検証を行っています。さらに、米国食品医薬品局（FDA）が主要なMCED検査に画期的な指定を与えるなど、規制当局の承認は、がん検診へのアプローチ方法のパラダイムシフトを示唆しています。これらの技術が成熟するにつれて、日常的な健康診断への統合が予防医学の新たな標準となり、早期発見が費用対効果の高い救命戦略へと変貌を遂げることが期待されます。

ヘルスケア政策と市場投資はどのようにMCED採用を加速させているか？

政府の政策、ヘルスケア・インフラ、投資動向は、MCED市場導入の軌道を形成する上で極めて重要な役割を果たしています。世界中のヘルスケアシステムが末期がん治療の経済的負担に取り組む中、早期発見戦略の費用対効果に関するコンセンサスが高まっています。いくつかの国の医療機関や保険業者は、MCED検査が患者の生存率を向上させながら、がん治療費全体を削減する可能性があることを認め、MCED検査の償還モデルを模索しています。例えば米国では、Medicare Multi-Cancer Early Detection Screening Coverage Actのような立法的取り組みが、高リスク集団におけるMCED診断へのアクセス拡大を目指しています。同様に、欧州委員会のキャンサー・プランは、早期発見への取り組みを優先し、リキッドバイオプシーに基づくスクリーニングの国家ヘルスケアプログラムへの統合を推進しています。政策主導の取り組みだけでなく、MCED分野へのベンチャーキャピタルやプライベートエクイティ投資の流入も、技術的進歩と市場拡大の加速に役立っています。業界の報告によると、MCEDソリューションを開発する精密腫瘍学の新興企業への資金提供は過去5年間で劇的に急増し、数十億米ドルの評価額は、この技術の破壊的可能性に対する投資家の信頼を反映しています。大手製薬企業も、MCED製品の共同開発・商業化のためにバイオテクノロジー企業と戦略的提携を結び、研究とイノベーションにさらに拍車をかけています。しかし、このような前向きな動向にもかかわらず、規制の標準化、検査の購入しやすさ、一般市民の認識といった課題は、依然として大量導入の障壁となっています。業界利害関係者、政策立案者、ヘルスケア提供者の協力的な取り組みを通じてこれらのハードルに対処することは、MCEDが早期がん発見のための広範かつ公平なソリューションとなることを確実にする上で極めて重要です。

MCEDの将来を形作る市場促進要因は何か？

世界の多重がん早期発見市場の成長は、急速な技術進歩、精密医療の採用拡大、世界のがん負担の増加など、いくつかの要因によってもたらされます。次世代シークエンシング（NGS）とデジタルPCRにおける技術的ブレークスルーは、MCED検査の感度と特異度を大幅に向上させ、早期がん検出の信頼性を高めています。診断ワークフローへのAIとビッグデータ解析の統合もまた、バイオマーカー探索を合理化し、がんシグネチャーの迅速かつ正確な同定を可能にしています。さらに、個人の遺伝子プロファイルに合わせて治療やスクリーニングを行う個別化医療へのシフトが、高度なMCEDソリューションへの需要を促進しています。がん早期発見のメリットに対する認識が高まり、患者が積極的なヘルスケアの選択肢を求めるようになっていることから、消費者行動も重要な促進要因となっています。また、DTC（Direct-to-Consumer：消費者直接）遺伝子検査の普及が進んでいることも市場拡大に寄与しており、個人が個別化された健康モニタリング戦略の一環としてMCED検査を選択しています。最終用途の観点からは、病院、診断研究所、研究機関がMCED技術を採用する主要な採用者であり、これらの検査を日常的ながん検診プログラムに組み込んでいます。コンパニオン診断や治療モニタリングなど、腫瘍学以外にもMCEDの応用が広がっており、市場機会はさらに広がっています。さらに、がん死亡率の低下を目指す政府の取り組みが、MCEDの採用を支援する政策枠組みを後押ししています。また、新興国では、ヘルスケアインフラの改善と可処分所得の増加に後押しされ、高度診断薬に対する需要が急増しています。市場の成長が期待される一方で、規制の複雑さ、遺伝子検査をめぐる倫理的配慮、大規模な検証研究の必要性といった課題に対処しなければ、長期的な採用を維持することはできません。とはいえ、技術革新が限界にチャレンジし続ける中、MCEDは将来のがん予防と早期介入の礎石となる準備が整っています。

セグメント

タイプ（遺伝子パネル＆LDT、リキッドバイオプシー）、最終用途（病院、研究機関、その他）

調査対象企業の例

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company（BD）
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

一般的に行われているLLMや業界特化型SLMへのクエリに頼るのではなく、私たちは世界中のドメイン専門家によって精選されたコンテンツを集約したリポジトリを構築しました。その中には、動画の文字起こし、ブログ、検索エンジンを用いた調査、さらには膨大な企業データ、製品・サービス情報、市場データが含まれています。

関税影響係数

私たちは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32245

Global Multi Cancer Early Detection Market to Reach US$2.6 Billion by 2030

The global market for Multi Cancer Early Detection estimated at US$1.1 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Gene Panel & LDT, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Liquid Biopsy segment is estimated at 18.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 20.4% CAGR

The Multi Cancer Early Detection market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$556.8 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Multi-Cancer Early Detection Market - Key Trends & Drivers Summarized

How is Multi-Cancer Early Detection Reshaping Oncology Diagnostics?

The landscape of cancer detection is undergoing a seismic shift with the advent of Multi-Cancer Early Detection (MCED) technologies, a breakthrough that promises to revolutionize oncology diagnostics. Unlike conventional cancer screenings that target only a handful of malignancies-such as mammograms for breast cancer or colonoscopies for colorectal cancer-MCED tests utilize advanced genomic, epigenomic, and proteomic biomarkers to simultaneously detect multiple cancer types in a single assay. This is achieved through liquid biopsies, which analyze circulating tumor DNA (ctDNA), RNA signatures, and other molecular alterations in blood samples. As cancer remains a leading global cause of mortality, early detection is critical to improving survival rates. According to the World Health Organization (WHO), late-stage diagnoses account for a substantial proportion of cancer-related deaths, highlighting the urgent need for early, non-invasive, and comprehensive screening solutions. With artificial intelligence (AI) and machine learning (ML) algorithms enhancing biomarker identification, MCED tests are now more accurate, scalable, and accessible than ever before. Several biotech firms and research institutions have made significant strides in validating these tests through large-scale clinical trials, demonstrating their potential to identify cancers even before symptoms appear. The promise of reducing the burden of late-stage cancer diagnoses and improving patient outcomes has generated unprecedented excitement in the medical community, investors, and regulatory agencies alike.

What Role Do Liquid Biopsies and AI Play in Advancing MCED?

At the core of MCED technology lies the integration of liquid biopsies and artificial intelligence, two game-changing innovations that have significantly elevated the accuracy and efficiency of multi-cancer screening. Traditional tissue biopsies, while effective, are often invasive, expensive, and limited to specific cancer types. Liquid biopsies, in contrast, offer a minimally invasive alternative that can detect a broad spectrum of cancers by identifying tumor-derived genetic fragments in the bloodstream. This technique has been particularly beneficial in detecting hard-to-screen cancers, such as pancreatic, ovarian, and esophageal malignancies, which often remain undiagnosed until advanced stages. AI-driven pattern recognition further amplifies the power of MCED by rapidly analyzing vast datasets of genetic, proteomic, and metabolic markers to differentiate between benign and malignant signals. AI models trained on millions of patient samples can refine diagnostic accuracy, minimize false positives and negatives, and even predict the tissue of origin for detected cancers. The growing adoption of AI in MCED has also enabled continuous learning, where algorithms evolve to recognize emerging cancer subtypes and adapt to new molecular discoveries. Notably, companies such as GRAIL, Guardant Health, and Exact Sciences have spearheaded efforts in commercializing AI-powered liquid biopsy tests, with extensive clinical validation backing their efficacy. Furthermore, regulatory approvals, such as the breakthrough designation granted by the U.S. Food and Drug Administration (FDA) for leading MCED tests, signal a paradigm shift in how cancer screening is approached. As these technologies mature, their integration into routine health check-ups is expected to become a new standard in preventive medicine, transforming early detection into a cost-effective, life-saving strategy.

How Are Healthcare Policies and Market Investments Accelerating MCED Adoption?

Government policies, healthcare infrastructure, and investment trends play a pivotal role in shaping the trajectory of MCED market adoption. As healthcare systems worldwide grapple with the economic burden of late-stage cancer treatments, there is growing consensus on the cost-effectiveness of early detection strategies. Several national health agencies and insurance providers are exploring reimbursement models for MCED tests, acknowledging their potential to reduce overall cancer treatment costs while improving patient survival rates. In the United States, for instance, legislative efforts such as the Medicare Multi-Cancer Early Detection Screening Coverage Act aim to expand access to MCED diagnostics among high-risk populations. Similarly, the European Commission’s Cancer Plan has prioritized early detection initiatives, pushing for greater integration of liquid biopsy-based screenings into national healthcare programs. Beyond policy-driven efforts, the influx of venture capital and private equity investments in the MCED sector has been instrumental in accelerating technological advancements and market expansion. According to industry reports, funding for precision oncology startups developing MCED solutions has surged dramatically over the past five years, with multi-billion-dollar valuations reflecting investor confidence in the technology’s disruptive potential. Leading pharmaceutical giants have also entered strategic partnerships with biotech firms to co-develop and commercialize MCED products, further fueling research and innovation. However, despite these positive trends, challenges such as regulatory standardization, test affordability, and public awareness remain barriers to mass adoption. Addressing these hurdles through collaborative efforts between industry stakeholders, policymakers, and healthcare providers will be crucial in ensuring MCED becomes a widespread and equitable solution for early cancer detection.

What Are the Key Market Drivers Shaping the Future of MCED?

The growth in the global Multi-Cancer Early Detection market is driven by several factors, including rapid technological advancements, increasing adoption of precision medicine, and the rising burden of cancer worldwide. Technological breakthroughs in next-generation sequencing (NGS) and digital PCR have significantly enhanced the sensitivity and specificity of MCED tests, making them more reliable for early-stage cancer detection. The integration of AI and big data analytics into diagnostic workflows has also streamlined biomarker discovery, allowing for faster and more accurate identification of cancer signatures. Additionally, the shift toward personalized medicine, where treatments and screenings are tailored to individual genetic profiles, has fueled demand for advanced MCED solutions. Consumer behavior is another critical driver, as awareness about the benefits of early cancer detection grows and patients increasingly seek proactive healthcare options. The rising prevalence of direct-to-consumer (DTC) genetic testing has also contributed to market expansion, with individuals opting for MCED tests as part of their personalized health monitoring strategies. From an end-use perspective, hospitals, diagnostic laboratories, and research institutions are among the key adopters of MCED technologies, integrating these tests into routine cancer screening programs. The expanding applications of MCED beyond oncology-such as in companion diagnostics and treatment monitoring-have further broadened market opportunities. Additionally, government initiatives aimed at reducing cancer mortality rates have driven policy frameworks that support MCED adoption. Emerging economies are also witnessing a surge in demand for advanced diagnostics, fueled by improving healthcare infrastructure and increasing disposable incomes. While market growth is promising, challenges such as regulatory complexities, ethical considerations surrounding genetic testing, and the need for large-scale validation studies must be addressed to sustain long-term adoption. Nevertheless, as innovation continues to push boundaries, MCED is poised to become a cornerstone in the future of cancer prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Multi Cancer Early Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Gene Panel & LDT, Liquid Biopsy); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company (BD)
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Multi Cancer Early Detection - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Cancer Prevalence Drives Accelerated Demand for Early Detection Technologies
    • Growing Investment in Liquid Biopsy and Non-invasive Testing Expands Market Opportunities for Multi Cancer Early Detection
    • Advances in Molecular Diagnostics and AI-driven Algorithms Propel Growth in Multi Cancer Early Detection Solutions
    • Rising Demand for Personalized Healthcare Solutions Strengthens the Business Case for Multi Cancer Early Detection
    • Surge in Preventive Healthcare Initiatives and Early Screening Programs Stimulates Adoption of Multi Cancer Detection Technologies
    • Regulatory Support and Approvals for Multi Cancer Early Detection Tests Expand Market Reach
    • Increasing Consumer Awareness of Cancer Risk Factors and Early Detection Benefits Accelerates Market Adoption
    • Technological Advancements in Biomarker Discovery Enhance the Sensitivity and Accuracy of Multi Cancer Early Detection Tests
    • Rising Focus on Minimally Invasive Diagnostic Methods Drives Demand for Multi Cancer Detection Solutions
    • The Expansion of Cancer Screening Guidelines and Reimbursement Policies Generates Growth in the Multi Cancer Early Detection Market
    • Growth in Telemedicine and Remote Healthcare Services Expands the Reach of Multi Cancer Detection Technologies in Rural Areas
    • The Rise in Targeted Cancer Therapies and Precision Medicine Strengthens Demand for Early Detection and Diagnosis Solutions
    • Increased Focus on Early Disease Intervention and Cost-effective Cancer Management Drives Adoption of Multi Cancer Early Detection
    • Surge in Government Funding for Cancer Research and Early Screening Drives Technological Advancements in Multi Cancer Detection
    • The Growing Use of Wearable Devices and Health Apps for Cancer Monitoring Expands Opportunities for Integration with Early Detection Solutions
    • The Emergence of Multi-omics Approaches in Cancer Detection Expands Market Potential for Next-generation Diagnostic Tools
    • Rising Global Cancer Awareness and Screening Initiatives in Developing Economies Boost Demand for Multi Cancer Detection Solutions
    • Strategic Partnerships Between Biotech Firms and Healthcare Providers Propel Market Growth and Innovation in Early Detection Technologies
    • The Increasing Incidence of Cancer in Younger Populations Expands the Addressable Market for Early Detection Tools
    • Growing Interest in Cancer Prevention and Early Detection for High-risk Populations Stimulates Demand for Multi Cancer Screening Tests
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multi Cancer Early Detection Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Gene Panel & LDT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Gene Panel & LDT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AUSTRALIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • INDIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • LATIN AMERICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MIDDLE EAST
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AFRICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION